Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

DISEASE CHARACTERISTICS: * Diagnosis of high-risk neuroblastoma, meeting one of the following criteria: * Refractory disease, defined as no response, mixed response, or progressive disease after completion of induction therapy administered according to clinical trials COG-A3973 or COG-ANBL0532 (or other similar high-intensity induction regimen) * Relapsed following high-dose chemoradiotherapy including autologous stem cell transplantation * Achieved a complete remission (CR), very good partial remission (VGPR), or partial remission (PR) after ≤ 2 different salvage regimens, as defined by the following: * In CR after treatment with some form of salvage therapy (e.g., ¹³¹I-MIBG, antibody-based therapy, or any other COG or NANT salvage-therapy regimen) * In VGPR or PR after salvage therapy * No more than 3 sites of skeletal disease as determined by an ¹²³I-MIBG scan (for regional involvement of the skeleton \[e.g., pelvis, spine\], the tumor involvement should be \< 25% of the site) * Bone marrow involvement (\< 25% neuroblasts) by morphologic exam within the past 2 weeks * Patients with soft tissue disease are eligible provided they exhibit either a VGPR or PR in the primary soft tissue mass and in any sites of metastatic soft tissue disease * Disease status meeting one of the following criteria: * Minimal residual disease * Disease considered responsive to a salvage regimen * Stable disease * No rapidly progressive disease * Donors must meet one of the following criteria: * Matched, related donor (6/6 or 5/6) (bone marrow donor allowed) * HLA-matched unrelated donor (10/10 match on high-resolution \[HR\] typing of HLA-A, B, C, DRB1, and DQB1) * One allele- or antigen-mismatched unrelated donor (9/10 match on HR typing), mismatched at HLA-C only * One allele- or antigen-mismatched unrelated donor (9/10 match on HR typing), mismatched at HLA-A, B, DRB1, or DQB1 (only when HLA-C mismatch is not available) PATIENT CHARACTERISTICS: * Karnofsky/Lansky performance status 60-100% * ANC \> 500/mm\^3 * Creatinine clearance or radioisotope GFR ≥ 60 mL/min * Total bilirubin \< 3.0 mg/dL * AST or ALT \< 5 times upper limit of normal * Shortening fraction ≥ 25% by ECHO OR ejection fraction \> 30% by MUGA * FEV\_1 and DLCO ≥ 30% OR normal chest x-ray, pulse oximetry, and venous blood gas * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No active or recent (within the past 30 days) fungal infection * No proven or suspected sepsis, pneumonia, or meningitis unless appropriate therapeutic measures have been initiated to control the infection and systemic signs are no longer life-threatening * No requirement for oxygen or ventilator support PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior tandem autologous stem cell transplantations (according to clinical trial COG-ANBL0532) allowed * No prior allogeneic hematopoietic stem cell transplantation * More than 2 months since prior autologous stem cell transplantation, myeloablative therapy, total-body irradiation, whole abdominal radiotherapy, or therapeutic ¹³¹I-MIBG * More than 3 weeks since prior chemotherapy, immunotherapy (including anti-GD2 regimen), or biologic response modifiers and recovered * More than 2 weeks since prior local radiotherapy to the sites of metastatic disease